Editorial

• Volume 6 Number 11/12 November/December 2005

Conference reports

• 7th Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13-16 November 2005, Dublin, Ireland

• Monitoring side effects in resource limited countries

• Uridine supplement reverses thymidine-induced lipoatrophy

• Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

• Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

• Niacin has beneficial effect on lipids but no reduction in abdominal fat

• Gluteal implants used to replace lost buttock fat

• 10th European AIDS Conference, 17-20 November 2005, Dublin, Ireland

• Pregnancy studies at EACS

Antiretrovirals

• Named-patient access programme available in UK for new protease inhibitor darunavir (TMC114)

• Tibotec discontinues TMC125 study C227: phase III studies continue

• New Kaletra tablet formulation (meltrex) approved by FDA

• GSK closes Phase 3 studies of its CCR5 inhibitor aplaviroc and terminates development programme

• Schering discontinues Phase II studies of vicriviroc in treatment naive patients

• FDA issues approvable letter for Bioject needle-free injection device

• Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)

PMTCT and maternal health

• US pregnancy guidelines updated

Treatment access

• Brazil’s deal with Abbott is challenged in courts

Resistance

• Cost effectiveness of resistance testing for treatment-naive patients

Other news

• European activists denounce pricing increases for HIV drugs as 'unbearable'

On the web

• Guidelines for the use of antiretroviral agents in pediatric HIV infection

• American Association For The Study of Liver Diseases (AASLD), November 11-15, 2005 San Francisco

• Medscape articles and online papers

• Community newsletters and journals

• HIV inSite Knowledge Base

• Amedeo HIV Medicine

PDFs

• Volume 6 Number 11/12 November/December 2005 PDF